epidermal-growth-factor and Ventricular-Dysfunction--Left

epidermal-growth-factor has been researched along with Ventricular-Dysfunction--Left* in 1 studies

Other Studies

1 other study(ies) available for epidermal-growth-factor and Ventricular-Dysfunction--Left

Article	Year
Effects of endogenous serum neuregulin-1β on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2018, Volume: 23, Issue:7 Improved left ventricular ejection fraction (LVEF) following administration of recombinant human Neuregulin-1β (NRG), epidermal growth factor (EGF) involved in cardiomyocyte repair/survival, has been observed in patients with systolic heart failure (HF).. Serum NRG was measured by ELISA in 248 patients with NYHA class I-IV HF.. NRG exhibited a marginally significant effect on LVEF trajectory over 11 months (p = 0.07). There is no apparent level of NRG that predicts improved survival.. There is a potential relationship between serum NRG and improved LVEF, indicating the need to investigate the utility of NRG in predicting HF outcomes, including LVEF maintenance. Topics: Epidermal Growth Factor; Female; Heart Failure; Humans; Male; Middle Aged; Neuregulin-1; Neuregulins; Predictive Value of Tests; Prognosis; Stroke Volume; Ventricular Dysfunction, Left	2018

Article

Year

Effects of endogenous serum neuregulin-1β on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction.

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2018, Volume: 23, Issue:7

Improved left ventricular ejection fraction (LVEF) following administration of recombinant human Neuregulin-1β (NRG), epidermal growth factor (EGF) involved in cardiomyocyte repair/survival, has been observed in patients with systolic heart failure (HF).. Serum NRG was measured by ELISA in 248 patients with NYHA class I-IV HF.. NRG exhibited a marginally significant effect on LVEF trajectory over 11 months (p = 0.07). There is no apparent level of NRG that predicts improved survival.. There is a potential relationship between serum NRG and improved LVEF, indicating the need to investigate the utility of NRG in predicting HF outcomes, including LVEF maintenance.

Topics: Epidermal Growth Factor; Female; Heart Failure; Humans; Male; Middle Aged; Neuregulin-1; Neuregulins; Predictive Value of Tests; Prognosis; Stroke Volume; Ventricular Dysfunction, Left

2018